How to Find the Cheapest Online Weight Loss Injections

Why Weight Loss Injections Cost So Much Without Help

GLP-1 receptor agonists are among the most effective obesity medications ever studied. In STEP-1 (N=1,961), semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) [1]. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001) [2].

That clinical performance comes with a price tag. Novo Nordisk set the list price of Wegovy (semaglutide 2.4 mg) at approximately $1,349 per month. Eli Lilly priced Zepbound (tirzepatide) at approximately $1,060 per month. Without insurance or a savings program, most patients pay those figures out of pocket.

Why Insurance Often Refuses to Cover These Drugs

Many commercial insurance plans categorize GLP-1 agonists for obesity as "lifestyle drugs" and exclude them from formulary coverage. Medicare Part D was explicitly prohibited from covering weight-loss drugs until the Treat and Reduce Obesity Act proposals began advancing in Congress. As of early 2025, coverage remains inconsistent.

The result: tens of millions of clinically eligible patients, defined by the FDA label as adults with a BMI of 30 or higher, or BMI <27 with a weight-related comorbidity, are left to find their own way to affordable access.

The Cost Gap Is Real but Closeable

The difference between $1,349 per month and $199 per month is the difference between a medication that is simply out of reach and one that is sustainable for a year or more. The strategies below close that gap through legitimate, medically supervised pathways.

Manufacturer Savings Cards: The Fastest Path to Low Cost

If you have commercial insurance that covers GLP-1s at any tier, manufacturer savings cards can reduce your copay dramatically. These are not coupons: they are contractual co-pay assistance programs run by the drug makers themselves.

NovoCare Savings Card for Wegovy

Novo Nordisk's NovoCare program offers eligible, commercially insured patients Wegovy for as low as $0 per month for the first 13 fills [3]. Eligibility rules apply: Medicare, Medicaid, and government-funded insurance programs do not qualify. Income caps vary by program year.

To enroll, visit the NovoCare portal directly or ask the telehealth or in-person prescriber to run an eligibility check at the point of care. Many patients who think they do not qualify actually do.

Eli Lilly's Savings Card for Zepbound

Eli Lilly offers a savings card that brings Zepbound to as low as $25 per month for commercially insured patients and $550 per month for uninsured patients through the Lilly Insulin Value Program's expanded format [4]. The $550 self-pay option is meaningful: it is roughly 48% below list price, no insurance required.

Lilly also offers Zepbound in single-dose vials at a lower list price than the auto-injector pens. As of late 2024, the 2.5 mg and 5 mg vials were priced at $399 per month, making them the lowest-cost FDA-approved tirzepatide option for self-pay patients [5].

Compounded Semaglutide and Tirzepatide: The Lowest-Cost Legal Option

Compounded GLP-1 medications are copies of the active ingredient (semaglutide or tirzepatide base) produced by 503A or 503B compounding pharmacies in the United States. When the brand-name drugs are on the FDA shortage list, compounding is legal under federal law [6].

Prices run from approximately $150 to $400 per month depending on the dose and the platform.

How Compounding Works Legally

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed compounding pharmacies to prepare personalized medications when a commercial drug is unavailable or a patient needs a different formulation [6]. Section 503B covers outsourcing facilities that compound in larger batches for office use.

Semaglutide remained on the FDA drug shortage list through most of 2024. Tirzepatide shortages were also declared. As long as a drug remains on that list, compounding pharmacies may legally prepare copies. The FDA publishes an updated shortage list at fda.gov [7].

Important: The FDA issued warning letters to compounders using salt forms of semaglutide (semaglutide sodium, semaglutide acetate) rather than the base form used in Ozempic and Wegovy. Only compounders using semaglutide base are operating within current FDA guidance [8].

What to Look for in a Compounding Pharmacy

Not all compounding pharmacies are equal. A legitimate compounding pharmacy dispensing GLP-1s should:

• Hold a valid state pharmacy license (verifiable through the NABP database)
• Be accredited by PCAB (Pharmacy Compounding Accreditation Board) or operate as an FDA-registered 503B outsourcing facility
• Require a prescription from a licensed U.S. Prescriber
• Provide a Certificate of Analysis (COA) from a third-party lab confirming potency and sterility
• Never ship internationally or advertise "no prescription required"

Patients should ask the telehealth platform they are using which specific pharmacy compounds their medication and request the COA on demand.

Compounded vs. Brand: The Clinical Trade-Off

Compounded semaglutide uses the same active peptide sequence as Ozempic and Wegovy but is not FDA-approved as a finished drug product. It has not gone through the same manufacturing quality review. That is not the same as saying it is dangerous, but it does mean the patient accepts a small additional uncertainty about potency and sterility compared to the brand product.

For patients who cannot afford $1,349 per month, a well-sourced compounded product from a PCAB-accredited pharmacy may be a reasonable medically supervised option. For patients who can access brand-name product through savings cards, that is the lower-risk path.

The HealthRX clinical team uses the following decision framework when advising patients on cost optimization:

1. Check commercial insurance first. Even a Tier 3 or Tier 4 drug benefit can reduce cost below $200/month with a savings card stacked on top.
2. Apply the manufacturer savings card regardless. Run eligibility before assuming you do not qualify.
3. If uninsured, compare Zepbound vials ($399/month) against compounded semaglutide ($150 to $400/month) and choose based on your comfort with compounded medications and your prescriber's recommendation.
4. If cost still prohibits access, apply for the Novo Nordisk Patient Assistance Program (PAP) or the Lilly Cares Foundation program, which provide medications free of charge to income-qualifying patients.
5. Never purchase from a source that does not require a prescription. Any site selling injectable GLP-1s without a consultation is operating illegally and may be supplying counterfeit or contaminated product.

Telehealth Platforms: Where to Get a Prescription Without Breaking the Bank

Telehealth companies have made GLP-1 prescriptions more accessible by eliminating the cost of an in-person specialist visit. Some platforms also compound medications in-house through affiliated pharmacies, which is how they advertise prices as low as $149 to $199 per month.

What a Legitimate Telehealth GLP-1 Visit Includes

A proper telehealth visit for a weight-loss injection prescription includes:

• A synchronous or asynchronous consultation with a licensed U.S. Physician, NP, or PA
• Review of your BMI, weight history, and relevant comorbidities
• Contraindication screening (personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis)
• Lab review if applicable (HbA1c, thyroid function, lipid panel)
• A written treatment plan with a titration schedule
• Follow-up check-ins at 4 to 8 week intervals

Platforms that skip these steps to offer a faster checkout are not providing medical care. They are selling a product.

How to Compare Telehealth Platform Costs

| What to Examine | Questions to Ask | |---|---| | Total monthly cost | Does the fee include medication, shipping, and follow-up visits? | | Compounded vs. Brand | Which pharmacy compounds the medication? Is a COA available? | | Titration flexibility | Will the provider adjust your dose without an extra fee? | | Cancellation terms | Is there a long-term contract or penalty for stopping? | | Lab costs | Are labs billed separately or included? |

Subscription fees vary widely. Some platforms charge $0 for the consultation and build margin into the medication price. Others charge $99 to $199 per month for membership plus the cost of medication. Neither model is inherently better; what matters is the total out-of-pocket figure and whether real medical oversight is included.

Patient Assistance Programs: Free Medication for Low-Income Patients

Both Novo Nordisk and Eli Lilly operate formal patient assistance programs (PAPs) that provide medication at no cost to patients who meet income and insurance criteria.

Novo Nordisk Patient Assistance Program

The Novo Nordisk PAP covers Wegovy for patients who:

• Have a household income at or below 400% of the federal poverty level
• Are uninsured or have insurance that does not cover the medication
• Are a U.S. Resident with a valid prescription

Applications are submitted through NovoCare or through the prescriber's office. Processing typically takes 2 to 4 weeks [3].

Lilly Cares Foundation

The Lilly Cares Foundation covers Zepbound and other Lilly medications for patients who meet income guidelines (generally at or below 400% of the federal poverty level) and lack adequate insurance coverage [4]. A prescriber must submit the application on the patient's behalf.

These programs are underutilized. The American Diabetes Association's Standards of Care in Diabetes (2024) explicitly states: "Clinicians should proactively assess cost barriers and connect patients with manufacturer assistance programs" [9].

GoodRx, Costco, and Cash-Pay Pharmacies: Marginal But Real Savings

For brand-name GLP-1 medications, GoodRx and similar discount aggregators rarely produce meaningful savings because the list price is so high. GoodRx prices for Wegovy typically run $1,100 to $1,300 per month, well below list but still unaffordable for most.

Costco Pharmacy and Mark Cuban's Cost Plus Drugs (costplusdrugs.com) offer lower prices on some generic medications, but as of early 2025, neither carries compounded or brand GLP-1 injectables at prices competitive with telehealth-affiliated compounding pharmacies.

Cash-pay pricing at community pharmacies varies by region. Calling three to five local pharmacies with the exact NDC number of the medication can occasionally surface a price 10 to 15% below the typical cash rate. It is worth a 20-minute phone session.

Red Flags: How to Spot Illegal or Dangerous Sources

The FDA has issued multiple safety warnings about counterfeit and subpotent GLP-1 products sold through unregulated online channels [8]. The risks include:

• Wrong dosing: Counterfeit products have been tested at 50% to 200% of the labeled potency.
• Contamination: Non-sterile compounding can introduce bacterial endotoxins that cause serious infections.
• No clinical oversight: Without a prescriber, side effects like nausea, vomiting, gastroparesis, and rare but serious pancreatitis go unmonitored.

Specific red flags include:

• No prescription required
• Claims of "research use only" or "not for human use" (a common regulatory workaround for peptide vendors)
• Payment only in cryptocurrency or wire transfer
• No U.S. Return address or customer service phone number
• Prices below $80 per month for any GLP-1 injectable

The FDA's MedWatch program accepts reports of suspected counterfeit or substandard drug products at fda.gov/safety/medwatch [10].

How to Talk to Your Doctor About Cost

Many patients do not raise cost concerns with their prescribers, assuming the conversation will be awkward or unproductive. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states directly: "Clinicians should discuss medication costs and coverage with patients before prescribing, and should document cost-related barriers in the medical record" [11].

Practical talking points:

• "My insurance doesn't cover this. Can you prescribe tirzepatide vials to use the $399 Lilly self-pay option?"
• "Is a compounded version medically appropriate for me given my history?"
• "Can your office submit a prior authorization to my insurer, and what documentation do you need from me?"
• "Am I eligible for the Novo Nordisk or Lilly patient assistance program?"

A prescriber who dismisses these questions is not providing complete care. Consider seeking a second opinion from a telehealth obesity medicine specialist if your primary care provider is not engaged on cost.

Prior Authorization: How to Fight a Denial

If your insurance denied a GLP-1 prior authorization, you have the right to appeal. The process is time-consuming but succeeds in a meaningful percentage of cases.

Building a Strong Appeal

A strong prior authorization appeal for semaglutide or tirzepatide typically includes:

• Documentation of a BMI of 30 or higher, or BMI <27 with an obesity-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, or cardiovascular disease)
• Evidence of previous weight-loss attempts (diet programs, other medications)
• A letter of medical necessity from the prescriber citing the FDA-approved indication
• Reference to the American Heart Association's 2023 scientific statement on obesity and cardiovascular risk, which classifies obesity as a chronic disease requiring long-term pharmacological management [12]

The Obesity Medicine Association offers a prior authorization toolkit that prescribers can download and use directly. Patients can request it through their provider's office.

The Lowest Realistic Monthly Cost by Pathway

Summarizing the options by expected out-of-pocket cost for a typical maintenance dose:

| Pathway | Estimated Monthly Cost | Prescription Required | |---|---|---| | Brand Wegovy + NovoCare savings card (insured) | $0 to $99 | Yes | | Brand Zepbound + Lilly savings card (insured) | $25 to $99 | Yes | | Zepbound vials, self-pay | $399 | Yes | | Compounded semaglutide via telehealth | $150 to $400 | Yes | | Compounded tirzepatide via telehealth | $250 to $500 | Yes | | Novo Nordisk or Lilly PAP (income-qualifying) | $0 | Yes | | Brand without savings card or insurance | $1,060 to $1,349 | Yes |

No legitimate pathway exists below $150 per month for a clinically dosed, medically supervised GLP-1 injection program. Any price quoted below that threshold warrants serious scrutiny.